These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15598031)

  • 21. [Her2 positive breast cancer: practices].
    Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
    Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab: mechanisms of resistance and therapeutic opportunities.
    Calabrich A; Fernandes Gdos S; Katz A
    Oncology (Williston Park); 2008 Oct; 22(11):1250-8; discussion 1259, 1263. PubMed ID: 18980023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Slichenmyer WJ; Fry DW
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):67-79. PubMed ID: 11706398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
    Menendez JA; Lupu R
    J Clin Oncol; 2007 Jun; 25(17):2496-8; author reply 2499. PubMed ID: 17557968
    [No Abstract]   [Full Text] [Related]  

  • 29. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.
    Clark JJ; Provenzano M; Diggelmann HR; Xu N; Hansen SS; Hansen MR
    Otol Neurotol; 2008 Sep; 29(6):846-53. PubMed ID: 18636037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
    Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
    Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
    Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
    Bonneterre ME; Bonneterre J
    Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance.
    Roukos DH
    Ann Surg Oncol; 2010 Jan; 17(1):14-7. PubMed ID: 19841980
    [No Abstract]   [Full Text] [Related]  

  • 40. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.